Stories about sodium valproate
The Medicines and Healthcare products Regulatory Agency (MHRA) has today changed the licence for valproate medicines in the UK.
Sodium valproate must no longer be prescribed to women or girls of childbearing potential unless they are on the pregnancy prevention programme (PPP).
Norman Lamb, chair of the Science and Technology Committee, led the debate. He said that there had been “systematic failure” to warn women of the risks of valproate since the 1970s.
The EMA assesses and oversees the safety of medicines in the EU. The announced public hearing is part of the EMA’s review into the use of valproate-based medicines in women who are pregnant or of childbearing age.